AffyImmune Therapeutics, Inc. https://validator.w3.org/feed/docs/rss2.html AffyImmune Announces Plenary Oral Presentation on ICAM-1 Directed CAR T Therapy AIC100 at AACR 2025 AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer Registration for Navigating Advanced Thyroid Cancer: Unmet Needs and Innovations AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023 AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer AffyImmune Appoints Drs. Rick Rutter and Jorge Nieva to Board of Directors AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer Join Us Science Contact AffyImmune Therapeutics Named 2023 Scrip Award Finalist for Best Oncology R&D Advance Expanded Access Policy Opt-out preferences Privacy Statement (US) AffyImmune Therapeutics Announces Addition of Dr. Jim MulĂ© to its Scientific Advisory Board AffyImmune Co-founder Dr. Moonsoo Jin Receives Highly Selective R01 Grant from NCI AffyImmune Therapeutics’ AIC100 Granted Fast Track Designation for Treating Thyroid Cancer AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Research AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR T cells for Patients with Advanced, Refractory Thyroid Cancer AffyImmune Therapeutics Announces Hiring of Dr. Sonal Gupta as Senior Vice President and Head of Clinical Development AffyImmune Therapeutics to Present Poster at American Association for Cancer Research Annual Meeting AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital AffyImmune Therapeutics to Present Initial Clinical Results at Upcoming CAR-TCR Summit AffyImmune Therapeutics Announces Hiring of Matt Britz as Senior Vice President of Business Development AffyImmune Therapeutics Named 2023 Scrip Award Finalist for Best Oncology R&D Advance AffyImmune Announces Presentation on Affinity-Tuned CAR T Therapy AIC100 at ASCO 2024 AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024 Pipeline AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC ASCO 2023 Poster AffyImmune Therapeutics Adds Serial Entrepreneur Robert Forrester to Board of Directors AffyImmune Therapeutics Announces Clinical and Regulatory Advisory Board to Support Development of AIC100 in Solid Tumors About AffyImmune Therapeutics to Present Poster at 2024 American Association for Cancer Research Annual Meeting AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting AffyImmune Therapeutics Named 2023 Scrip Award Finalist for Best Oncology R&D Advance AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023 AffyImmune Therapeutics to Present at 2023 Cell & Gene Meeting on the Mesa AffyImmune Therapeutics